A US district court has granted an injunction sought by Incyte on the launch of Sun Pharma's recently approved Leqselvi for alopecia areata. In a brief filing with the National Stock Exchange (NSE ...

Sun Pharma successfully removed an injunction in the US on the launch of its Leqselvi for alopecia areata, a common form of hair loss, that was sought by rival Incyte. The decision in the US Court ...

After a legal decision delayed its entry last fall, Sun Pharma has received the all-clear to tap into the U.S. alopecia market with its JAK inhibitor Leqselvi, teeing up a potential showdown with ...

Sun Pharmaceutical Industries Ltd, which has been embroiled in a patent lawsuit in the US since last year over its specialty drug Leqselvi, received a favourable ruling from a court, paving the ...

Photograph: Francis Mascarenhas/Reuters Recent acquisitions, a favourable court ruling in the case of the hair loss drug ...

Indian benchmark Nifty 50 spent the day in the green. Nifty opened at 24,070 and ended the day at 24,329 gaining 289 points. It regained Friday’s losses and saw high momentum today. Out of the total ...

The injunction had temporarily barred Sun Pharma from launching Leqselvi in the United States due to an ongoing legal battle with Incyte Corporation. The appellate court's decision, which came shortly ...

Sun Pharmaceutical Industries stock ended 2.15 per cent higher on Friday after zooming by almost 5 per cent in the morning trade on the back of an announcement that a court ruling has cleared the deck ...

Sun Pharma has been locked in a patent infringement litigation with Incyte Corporation over LEQSELVI (deuruxolitinib). On April 9, 2025, the US Court of Appeals for the Federal Circuit held an ...

US Court vacates injunction, allowing Sun Pharma to launch Leqselvi Emkay Global suggests a royalty-based settlement with Incyte Leqselvi's US sales projected at $40 million in FY26, $124 million ...